As the cancer day care centre at AIIMS, Delhi, spills over, families hope decentralised treatment will cut costs, minimise ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

The other 743 women (median age, 49 years; range, 23-80; 71.5% white) received trastuzumab 6 mg/kg via IV every 3 weeks for 14 cycles. Invasive DFS served as the primary endpoint. OS served as a ...

every three weeks or IV trastuzumab monotherapy at a dose 6 mg per kilogram every three weeks for 14 cycles. Randomization was arranged as per clinical stage at presentation, specifically inoperable ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

Sodium-cooled fast reactors using metallic-alloy fuel are attracting attention because they are inherently safe and produce more fuel than they use.

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...